Wound healing is a complex process consisting of steps–hemostasis, inflammation, proliferation, and remodeling. The purpose of this multicenter, open-label, randomized, active-controlled, prospective, two-arm, phase IV clinical study was to evaluate and compare the safety, tolerability, and efficacy of fixed-dose combination (FDC) enteric-coated tablets of trypsin 96 mg + bromelain 180 mg + rutoside trihydrate 200 mg–Enzomac Forte with the enteric-coated tablets of trypsin-chymotrypsin 100000 AU–marketed formulation in the complex wound healing process. An open-label, randomized, parallel, active-controlled, two-arm, phase IV clinical study was conducted at 13 centers in India from December 02, 2017, to May 04, 2019. Adult patients aged 18-65 years (both inclusive) fulfilling the eligibility criteria were included. These patients were randomized into two treatment groups–FDC versus trypsin-chymotrypsin. Adverse events (AEs) and serious adverse events (SAEs) were recorded to evaluate and compare the safety and tolerability. The efficacy of both the treatment in the management of wound healing was noted and compared. AEs were reported in five patients; no SAEs were reported. No clinically significant differences in the occurrence of AEs were found; thus, both the treatments were safe and tolerable. The wound regeneration efficacy on day 10±2 was significantly higher with FDC as compared to trypsin-chymotrypsin. A significantly high improvement of total BWAT score with FDC as compared to trypsin-chymotrypsin was observed. FDC used by the authors in this study was found to be equally safe and tolerable and more effective than the marketed formulation used for wound healing after a minor surgical procedure.